Abstract
STn is a tumor-associated carbohydrate antigen with high prevalence across various solid tumor types, including ovarian and non-small cell lung cancer (NSCLC). While its expression is restricted in normal tissues, it presents with several tumor-associated proteins, such as MUC1 and MUC16. STn is thought to influence cancer progression by affecting cell adhesion, migration and propagation of invasiveness, and has been linked to advanced disease, chemotherapy resistance, and decreased survival. SGN-STNV is an investigational antibody–drug conjugate which directs monomethyl auristatin E (MMAE) to STn-expressing cells.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
